MACK

Merrimack Pharmaceuticals, Inc. Press Releases

$10.43
*  
0.34
3.37%
Get MACK Alerts
*Delayed - data as of Aug. 27, 2015  -  Find a broker to begin trading MACK now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results
8/10/2015 4:01:00 PM - PR Newswire
▲9.44 % Price Change since this news event. The Volume Ratio is 2.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
8/6/2015 8:00:00 AM - PR Newswire
▼-3.78 % Price Change since this news event. The Volume Ratio is 1.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call
8/3/2015 8:00:00 AM - PR Newswire
▲3.27 % Price Change since this news event. The Volume Ratio is 0.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
6/25/2015 3:18:00 PM - PR Newswire
▼-16.56 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


U.S. FDA Grants Priority Review for MM-398 New Drug Application
6/25/2015 7:00:00 AM - PR Newswire
▼-12.35 % Price Change since this news event. The Volume Ratio is 2.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
6/15/2015 4:01:00 PM - PR Newswire
▼-4.49 % Price Change since this news event. The Volume Ratio is 1.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
6/11/2015 5:00:00 PM - PR Newswire
▼-7.70 % Price Change since this news event. The Volume Ratio is 1.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
6/1/2015 4:12:00 PM - PR Newswire
▼-9.54 % Price Change since this news event. The Volume Ratio is 0.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


PharmaEngine Announces Filing New Drug Application (NDA) of MM-398 (PEP02) to Taiwan FDA as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
5/31/2015 11:20:00 PM - PR Newswire
▼-11.61 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day